- Home
- RNA vs MC Comparison
RNA vs MC Comparison
Compare RNA & MC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- MC
- Stock Information
- Founded
- RNA 2012
- MC 2007
- Country
- RNA United States
- MC United States
- Employees
- RNA N/A
- MC N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- MC Investment Managers
- Sector
- RNA Health Care
- MC Finance
- Exchange
- RNA Nasdaq
- MC Nasdaq
- Market Cap
- RNA 3.4B
- MC 3.6B
- IPO Year
- RNA 2020
- MC 2014
- Fundamental
- Price
- RNA $27.87
- MC $54.93
- Analyst Decision
- RNA Strong Buy
- MC Hold
- Analyst Count
- RNA 12
- MC 7
- Target Price
- RNA $68.25
- MC $61.83
- AVG Volume (30 Days)
- RNA 1.4M
- MC 1.0M
- Earning Date
- RNA 05-08-2025
- MC 04-23-2025
- Dividend Yield
- RNA N/A
- MC 4.73%
- EPS Growth
- RNA N/A
- MC N/A
- EPS
- RNA N/A
- MC 2.29
- Revenue
- RNA $8,927,000.00
- MC $1,283,653,000.00
- Revenue This Year
- RNA N/A
- MC $15.19
- Revenue Next Year
- RNA $135.33
- MC $16.57
- P/E Ratio
- RNA N/A
- MC $24.02
- Revenue Growth
- RNA N/A
- MC 45.14
- 52 Week Low
- RNA $21.51
- MC $47.00
- 52 Week High
- RNA $56.00
- MC $82.89
- Technical
- Relative Strength Index (RSI)
- RNA 45.31
- MC 51.93
- Support Level
- RNA $25.58
- MC $51.98
- Resistance Level
- RNA $33.62
- MC $55.50
- Average True Range (ATR)
- RNA 2.09
- MC 1.73
- MACD
- RNA -0.29
- MC 0.68
- Stochastic Oscillator
- RNA 28.53
- MC 88.19
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About MC Moelis & Company
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.